Literature DB >> 30975002

Postpartum endometritis and obstetrical sepsis associated with Eggerthella lenta. Case report and review of the literature.

Tatiana Priputnevich1, Lyudmila Lyubasovskaya2, Vera Muravieva3, Andrey Kondrakhin2, Alla Ignateva4, Alexey Gordeev3, Roman Shmakov5, Gennady Sukhikh5, Ekaterina Yarotskaya6.   

Abstract

Sepsis, associated with Eggerthella lenta is rarely reported, despite current possibilities for microorganisms isolation and identification. About 100 cases of bacteriemia associated with this pathogen have been reported so far. Postpartum infectious complications are mostly associated with bacterial inhabitants of gastrointestinal tract and vagina, including obligatory anaerobes. This case report highlights E. lenta-associated severe endometritis complicated by abdominal sepsis in a young healthy woman, and the challenges of antibacterial therapy.

Entities:  

Keywords:  Eggerthella lenta; Postpartum endometritis; bacteriemia; infectious complications; obstetrical sepsis

Mesh:

Year:  2019        PMID: 30975002     DOI: 10.1080/14767058.2019.1602602

Source DB:  PubMed          Journal:  J Matern Fetal Neonatal Med        ISSN: 1476-4954


  3 in total

1.  Sepsis caused by Eggerthelle lenta: a case report.

Authors:  Li-Chao Sun; Wan-Ling Xu; Jian-Nan Chai; Li Pang; Xiu-Xian Zang; Wei Li; Ji-Hong Xing
Journal:  World J Emerg Med       Date:  2022

2.  Immunometabolic Analysis of Mobiluncus mulieris and Eggerthella sp. Reveals Novel Insights Into Their Pathogenic Contributions to the Hallmarks of Bacterial Vaginosis.

Authors:  Ross McKenzie; Jason D Maarsingh; Paweł Łaniewski; Melissa M Herbst-Kralovetz
Journal:  Front Cell Infect Microbiol       Date:  2021-12-23       Impact factor: 5.293

Review 3.  Eggerthella lenta bacteremia successfully treated with ceftizoxime: case report and review of the literature.

Authors:  Shuming Jiang; Jianfei E; Dengchao Wang; Yanjiao Zou; Xiao Liu; Hualiang Xiao; Yuan Wen; Zongyao Chen
Journal:  Eur J Med Res       Date:  2021-09-20       Impact factor: 2.175

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.